Novozymes and DSM announce acquisitions; Symrise CEO contract extended to 2025

  • Sectors : Foods
  • Companies : Kerry Group | Givaudan | DSM | Symrise


Ratings and price correct at time of issue

Company Rating Date Previous Rating Date Closing Price
DSM OUTPERFORM 09/10/20 Neutral 13/02/20 19080c
Givaudan OUTPERFORM 24/03/20 Neutral 21/06/12 449000chf
Kerry Group OUTPERFORM 30/06/09 N/A N/A 10790c
Symrise OUTPERFORM 24/03/20 Neutral 15/01/19 12495c


It has been a busy week for M&A deals in the ingredients sector as Novozymes and DSM have announced acquisitions. Novozymes is to advance its position in human health and functional food through a 60% acquisition in Synergia Life Sciences (Synergia). Synergia produces a clinically-backed portfolio of probiotics for various applications across functional and dietary supplements, which Novozymes intends to integrate into its acquisition-led BioHealth portfolio. DSM is set to move up the vertical integration ladder through its acquisition of plant-based protein feedstock producer Vestkorn Milling (Vestkorn). Vestkorn supplies an array of protein, starches and dietary fibres used in plant-based protein production, which complements DSM’s existing sustainable food offering. Both deals emphasize the ongoing industry focus on building science-backed ingredients portfolios to meet growing functional health demand.

Download full report with analyst certification and important disclosures

Dec 2 2021, 08:30 GMT